A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Trial Profile

A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 May 2018

At a glance

  • Drugs Camidanlumab tesirine (Primary)
  • Indications Burkitt's lymphoma; Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; First in man
  • Sponsors ADC Therapeutics
  • Most Recent Events

    • 12 Dec 2017 Interim results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 11 Dec 2017 Interim results (n=86) published in the ADC Therapeutics media release.
    • 11 Dec 2017 According to an ADC Therapeutics media release, data from this trial was presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition (2017).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top